GSK to make grant info public

Share this article:
GlaxoSmithKline will join Pfizer and Eli Lilly in reporting educational and charitable grants.

The company will provide quarterly reports on grants to hospitals, teaching institutions, managed care organizations, professional associations, patient advocacy groups and CME companies starting in February of next year.

"GSK sponsors a range of third-party independent educational programs to increase awareness and knowledge of health-related issues,” said GSK president, North American pharmaceuticals, Chris Viehbacher in a statement. “By publishing information about our grants, we transparently identify the support we offer for independent and quality education to improve the delivery of health care for patients.”

Lilly began reporting its grants publicly in May 2007, and Pfizer followed suit a year later. In March, AstraZeneca vowed to publish grant information biannually.

In April, responding to an inquiry by Sen. Charles Grassley (R-IA) demanding to know whether they would follow Lilly's lead, several companies, including Bristol-Myers Squibb, Medtronic and Boston Scientific, also agreed to begin making information on educational grants and payments to physicians public, while others, including Abbott, Amgen and Merck, told the senator they were working on it. Only one of the firms Grassley wrote – Schering-Plough – declined outright.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.